Related Experiment Video

Updated: Jul 15, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

P J Roberts1, C J Der

  • 1Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA.

Oncogene
|May 15, 2007
PubMed

Insights

Mitogen-activated protein kinase (MAPK) cascades, particularly the ERK pathway, are crucial in cell regulation and implicated in cancer. This review details therapeutic strategies targeting the EGFR-Ras-Raf-MEK-ERK signaling network for cancer treatment.

Area of Science:

  • Cellular signaling pathways
  • Oncogenesis and cancer biology
  • Pharmacological interventions

Background:

  • Mitogen-activated protein kinase (MAPK) cascades regulate essential cellular functions like proliferation and survival.
  • Dysregulation of MAPK pathways, especially the extracellular signal-regulated kinase (ERK) pathway, is linked to cancer development.
  • The epidermal growth factor receptor (EGFR)-Ras-Raf-MEK-ERK signaling network is frequently altered in human cancers.

Purpose of the Study:

  • To review current therapeutic strategies targeting the EGFR-Ras-Raf-MEK-ERK signaling pathway.
  • To summarize ongoing research and development for novel cancer treatments focused on this pathway.
  • To highlight the significance of this pathway in human oncogenesis.

Main Methods:

  • Review of existing literature on MAPK signaling in cancer.
  • Analysis of therapeutic targets within the EGFR-Ras-Raf-MEK-ERK cascade.
  • Evaluation of pharmacologic inhibitors and their development status.

Main Results:

  • The Raf-MEK-ERK pathway is activated by Raf kinases and is a key effector of Ras.
  • Mutations in Raf and Ras, along with EGFR alterations, drive oncogenesis.
  • ERK activation promotes EGFR ligand expression, creating a tumor growth loop.

Conclusions:

  • The EGFR-Ras-Raf-MEK-ERK pathway represents a critical target for novel cancer therapies.
  • Target-based approaches are under intense investigation for therapeutic intervention.
  • Understanding this signaling network is vital for developing effective cancer treatments.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...